BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
See today's BioWorld
Home
» Chi-Med kicks off phase IIb/III study testing surufatinib in advanced biliary tract cancer
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Chi-Med kicks off phase IIb/III study testing surufatinib in advanced biliary tract cancer
April 5, 2019
By
David Ho
No Comments
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) has started a phase IIb/III study for its surufatinib candidate, HMPL-012, an oral small-molecule angio-immuno kinase inhibitor that can simultaneously block tumor angiogenesis and immune evasion.
BioWorld